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Abstract Glioma has been investigated for decades, but the
prognosis remains poor because of rapid proliferation, its ag-
gressive potential, and its resistance to chemotherapy or radio-
therapy. The mammalian target of rapamycin (mTOR) is high-
ly expressed and regulates cellular proliferation and cell
growth. MicroRNAs (miRNAs) are small non-coding RNAs
that regulate gene transcription and translation via up-
regulating or down-regulating the levels of miRNAs. This
study was conducted to explore the molecular functions of
miR-199a-3p in glioma. We detected the expression of miR-
199a-3p in glioma samples by quantitative PCR (qPCR).
Then, we transfected the U87 and U251 cell lines with miR-
199a-3p. Cellular proliferation, invasion, and apoptosis
were assessed to explain the function of miR-199a-3p.
PCR confirmed that the expression of miR-199a-3p was
lower in glioma samples combined with normal brain
tissues. The over-expression of miR-199a-3p might tar-
get mTOR and restrained cellular growth and prolifera-
tion but not invasive and apoptosis capability. Results
indicated that cellular proliferation was inhibited to reg-
ulate the AKT/mTOR signaling pathway by elevating
levels of miR-199a-3p. MiR-199a-3p in glioma cell
lines has effects similar to the tumor suppressor gene
on cellular proliferation via the AKT/mTOR signaling
pathway.
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Introduction
Malignant glioma is a lethal human primary brain tumor with
limited therapeutic options. Glioma is devastating due to dif-
fuse invasion, chemical, and radiation therapy resistance [1].
The PI3K/Akt/mTOR pathway in human tumor cells is often
constitutively activated [2]. Wangpaichitr et al. have demon-
strated that mTOR plays a pivotal role in cisplatin resistance
[3]. Moreover, cancer remains a poor prognosis, mainly attrib-
uted to the excessive activation of the PI3K-AKT/mTOR sig-
naling pathway [4–8]. Now, with the improvement of the
prognosis by targeting the mTOR, inhibitors have been used
for blocking the PI3K-AKT/mTOR signaling pathway and
have been preliminarily demonstrated to be an anticancer ther-
apeutic intervention in glioblastoma [9–12].
Evidence collected confirms that microRNAs (miRNAs)
are involved in the initiation, development, and prognosis of
cancer, and they have multiple roles in different tissues.
miRNAs are continuously being found to act in roles analo-
gous to tumor suppressors and oncogenes [13, 14]. Among
miRNAs analyzed, we found miR-199a-3p was detected to be
a significantly different expression in glioma cell lines
SHG139 compared with SHG139s (P<0.01). Subsequently,
a pre-experiment was carried out to define differential expres-
sions in glioma samples combined with normal brain tissues.
Furthermore, miR-199a-3p was a reduced expression in
endometrioid adenocarcinoma, papillary thyroid carcinoma,
ovarian cancer, and hepatocellular carcinoma [15–18]. In ad-
dition, thirteen nucleotides are complementary to miR-199a-
3p and mTOR sequences in the miRBase database. Besides,
many previous studies indicate that miR-199a-3p targets
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mTOR by luciferase reporter analysis [15, 17, 18], and cell
proliferation is modulated through inhibiting mTOR.
Materials and methods
Human tissue samples
Specimens of human brain tumors for the study were collected
from participants who underwent surgical removal of their
brain tumors at the Department of Neurosurgery, Brain and
Nerve Research Laboratory of the First Affiliated Hospital of
Soochow University (Suzhou, China). Of course, informed
consent was obtained from each patient who donated their
brain tissues for the research purpose. Six normal brain sam-
ples were obtained from people with traumatic brain injury,
for whom a partial resection of brain tissues was conducted for
decreasing the intracranial pressure. Brain tumors included 30
women and 31 men. The tumor group consists of 32 cases of
grade II (26 astrocytoma, 6 oligodendroglioma), 13 cases of
grade III (11 anaplastic astrocytoma, 2 anaplastic
ependymoma), and 16 cases of grade IV (glioblastoma), ac-
cording to the 2007 WHO classification system. The ages of
people at surgical resection were 40.62±15.64 years for grade
II and 47.89±15.21 years for grade III and grade IV. All hu-
man samples were used in accordance with the policies of the
institutional review board of the First Affiliated Hospital of
Soochow University.
Cell cultures and treatments
The human U87 and U251 glioma cell lines were purchased
from the Cell Bank Type Culture Collection of the Chinese
Academy of Sciences (Shanghai, China). Cells were grown in
Dulbecco’s modified Eagle’s medium (DMEM; Hyclone,
Thermo Fisher Scientific, Waltham, MA, USA) supplemented
with 10 % fetal bovine serum (FBS; Gibco, Invitrogen,
Carlsbad, CA, USA).
Cells were treated with 100 nmol/ml NVP-BEZ235
(Cayman Chemical, Ann Arbor, MI, USA) for 6 h for the cell
proliferation trial and 6 h for the Western blot analysis. Cells
treated in parallel with the same amount of dimethyl sulfoxide
(DMSO) served as controls.
Oligonucleotide transfection
For the miR-199a-3p over-expression, cells were transfected
with 100 nmol⁄L of miR-199a-3p mimics, which are small,
chemically modified double-strand RNA molecules that are
designed to mimic endogenous mature miRNAs. The trans-
fection rates in two human glioma cell lines, U87 and U251,
were determined by green fluorescence and flow cytometry.
The transfection efficiency was analyzed by flow cytometry;
the results suggested that transfection efficiency were greater
than 90 %. The entire transfection process was completed
using Lipofectamine 2000 (Invitrogen), according to the man-
ufacturer’s instructions.
Quantitative real-time PCR analysis
All of the RNA from cells and tissues was isolated using
TRIzol reagent (Invitrogen) for both messenger RNA
(mRNA) and miRNA analyses. For the analysis of the miR-
199a-3p expression, quantitative real-time PCR (qRT-PCR)
analyses were carried out using the All-in-One miRNA qRT-
PCR Detection Kit (GeneCopoeia, Rockville, MD, USA), ac-
cording to the manufacturer’s instructions (LightCycler 480
Roche). U6 was regarded as the internal control (miR-199a-3p
primer ID, hsmq-0715, Catalog#HmiRQP0289; U6 primer
ID, hsRNAU6, Catalog#HmiRQP9001; LightCycler 480
Roche). Relative levels of mTOR, P70S6K, 4EBP1, and
RHOA mRNAs were examined using SYBR green real-time
quantitative RT-PCR (qRT-PCR) (LightCycler480 Roche,
Switzerland) and were normalized to levels of GAPDH
mRNA. Relative expression was calculated using the 2−△△CT
method. All qRT-PCR analyses were carried out in triplicate,
and the data are presented as mean and standard deviation.
Flow cytometric analysis
Glioma cell lines (U87, U251) were cultured in 6-well plates
before transfecting with the negative control oligonucleotide
or mimics of miR-199a-3p. Cells were collected and fixed in
70 % cold ethanol at −4 °C for one night. Cells underwent
propidium staining (Beyotime Institute of Biotechnology,
Shanghai, China), and cell cycles were analyzed by flow cy-
tometry. The detection of apoptotic cells was performed by
using the PE Annexin V Apoptosis Detection Kit I (BD
Biosciences, Franklin, NJ, USA). U87 and U251were collect-
ed 72 h after transfection. Cells were washed twice with cold
PBS and then resuspended in 1× binding buffer at a concen-
tration of 1×106 cells/ml. Then, 5 μl of 7-AAD and 5 μl of PE
Annexin V were added to the culture tube with 100 μl of cell
suspension. Cells were incubated for 15 min in the dark at
room temperature (RT), and 400 μl 1× binding buffer was
added to each tube, which was analyzed by flow cytometry
within 1 h. All analyses were repeated three times.
CCK-8 assay
The proliferation of miR-199a-3p was detected by a cell
counting kit (CCK-8, Dojindo, China). The cells were
transfected with a negative control oligonucleotide, or mimics
of miR-199a-3p were seeded in 96-well plates at a density of
2000 cells/well. Following 6, 24, 48, and 72 h of incubation,
subsequently, CCK-8 was added with 10 μl per well and
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incubated 2 h again, after which the absorbance at 450 nmwas
measured (Thermo, MA, USA). The absorption of OD was
calculated as the mean±SD of six determinations per sample,
in three separate experiments.
In vitro invasion assay
U87 and U251 cells transfected with the negative control or
miR-199a-3p mimic oligonucleotides were cultured for 48 h,
and cells were suspended and transferred to 200 μl solution on
the top of Matrigel-coated invasion chambers (24-well insert,
8-μm pore size; BD Biosciences) with serum-free DMEM.
Then, 750-μl DMEM with 0.05 % FBS was added to the
lower chamber. After 72 h had elapsed, cells above the
matrigel were removed and cells were fixed with 4 % formal-
dehyde for 10 min and stained with 0.1 % crystal violet for 20
to 30 min. Invading cells were counted in six randomly select-
ed sites under a microscope.
Western blot
Cells were collected after culturing for 72 h and mechanically
lysed in the mixture lysis buffer for the Western blot and
phenylmethylsulfonyl fluoride (PMSF) (Beyotime Institute
of Biotechnology). The protein concentration was detected
by a bicinchoninic acid (BCA) protein assay kit (Beyotime
Institute of Biotechnology). The primary antibodies used were
anti-mTOR, anti-p-AKT, anti-P70S6K, anti-p-P70S6K, anti-
4E-BP1, anti-p-4E-BP1, anti-RHOA, anti-matr ix
metallopeptidase 2 (MMP2), anti-Caspase-3, and anti-
GAPDH (CST, MA, USA). Protein samples were separated
by 6 to 15 % SDS-PAGE and transferred to a nitrocellulose
membrane, which was blocked with 5 % bovine serum albu-
min (BSA) (Amresco, Solon, OH, USA) for 1 h at RT.
Membranes were incubated with primary antibodies overnight
at 4 °C. The membranes were washed and incubated with
HRP-conjugated secondary antibodies (Beyotime Institute of
Biotechnology) for 2 h. The signal was detected using en-
hanced chemiluminescence (ECL) (Thermo).
Immunofluorescence analysis
The cells were fixed with 4 % paraformaldehyde for 30 min
and blocked with BSA (Amresco) for 30 min. The cells were
then incubated with primary antibodies for the detection of p-
mTOR (diluted 1:50), p-AKT (diluted 1:200), and p-4E-BP1
(diluted 1:200) at 4 °C overnight and incubated with
tetramethylrhodamine isothiocyanate-labeled secondary anti-
body (diluted 1:400) at 37 °C for 1 h. Finally, cells were
stained with DAPI, and photos were taken with a fluorescence
Fig. 1 The expression of miR-199a-3p, mTOR, p70S6K, and RhoA in
glioma samples and normal brain tissue were assessed by qPCR. Data
were reported as 2−△△CT. a miR-199a-3p in human glioma samples
compared with normal brain tissues (asterisks, P<0.01), in low grade
(grade II) compared with high grade (grade III, grade IV) (ampersand,
P>0.05). bmTOR in glioma samples comparedwith normal brain tissues
(asterisks, P<0.01), mTOR expression with the increasing degree of
glioma (low-grade glioma vs. high-grade glioma; asterisks, P<0.01). c,
d The expression of p70S6K and RhoA in glioma samples compared with
normal brain tissues (asterisks, P<0.01) and in low grade and high grade
(ampersand, P>0.05)
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microscope (OLYMPUS BX50/BXFLA/DP70; Olympus
Co., Japan).
Immunohistochemistry analysis
U87 and U251 cells were incubated with the primary antibody
anti-Ki-67 (CST). Sections seeded with cells were incubated
according to manufacturer’s instructions offered by the Cell
and Tissue Staining Kit HRP-DAB system (R&D Systems,
Minneapolis, MN, USA).
Statistical analysis
Statistical analyses were conducted with SPSS 13.0 software
(SPSS Inc., Chicago, IL, USA). Differences between groups
were tested using a Student’s t test or ANOVA. Reported P
values were two-tailed and were considered statistically sig-
nificant when P<0.05.
Results
Expression of miR-199a-3p, mTOR, and its downstream
effector molecules in glioma samples
To gain further insight into the expression of miR-199a-
3p in glioma samples and normal brain tissues, quantita-
tive polymerase chain reaction (qPCR) was conducted in
6 normal brain tissues and 61 glioma samples. Results
showed that the expression of miR-199a-3p was lower in
glioma samples than normal brain tissues (P<0.01;
Fig. 1a), and there was no significant difference between
low-grade glioma (grade II) and high-grade (grade III,
grade IV) glioma (P>0.05; Fig. 1a). The expression of
mTOR in glioma samples was higher combined with nor-
mal brain tissues and increased with the increasing de-
gree of malignancy in glioma (low-grade glioma vs.
high-grade glioma, P<0.01; Fig. 1b). In addition, RhoA
and p70S6k expressions in glioma samples were higher
Fig. 2 a The expression of miR-199a-3p in U87 and U251 compared
with six normal brain tissues (asterisks, P<0.01). b The expression of
miR-199a-3p in cells transfected with miR-199a-3p (asterisks, P<0.01).
cCellular proliferationwas detected in U87 and U251 by cell counting kit
(CCK-8) after 6, 24, 48, and 72 h of incubation. Data were reported as
means±SD (asterisks, P<0.01), compared with cells transfected with
miR-199a-3p mimic negative control or untransfected cells. d mTOR in
U87 and U251 with miR-199a-3p over-expression compared with miR-
199a-3p mimic negative control (asterisks, P<0.01). e Cell cycle
modulation was restrained resulting in G1 phase increase (asterisks,
P<0.01) and S phase decrease (asterisk, P<0.05)
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than normal brain tissues (P<0.01; Fig. 1c, d) and had no
significant association in low-grade and high-grade glio-
ma samples (P>0.05; Fig. 1c, d). The expression of miR-
199a-3p in U87 and U251 cell lines was very low
(P<0.01; Fig. 2a).
Up-regulation of miR-199a-3p suppresses proliferation
in glioma cells
Glioma has a poor prognosis; it grows as rapidly as any other
malignancy. We conducted cellular proliferation assays in
U87 and U251 cells to assess whether the up-regulation of
miR-199a-3p has a suppressive effect on the growth of glioma
cells. The expression of miR-199a-3p was higher after cells
were transfected withmiR-199a-3pmimics (P<0.01; Fig. 2b).
As a result, we found that cell proliferation was distinctly
decreased in glioma cells after transfection with miR-
199a-3p (P<0.01; Fig. 2c). To gain further insight into
cell cycle modulation, flow cytometry analysis was per-
formed in U87 and U251 cells. Results revealed that the
G1 phase (P<0.01; Figs. 2e and 3a) was increased, and
the S phase was decreased (P<0.05; Figs. 2e and 3a) in
cel l s with the over-expression of miR-199a-3p.
Immunohistochemistry in U87 and U251 cells transfected
with miR-199a-3p showed reduced Ki-67, compared with
negative control glioma cells (Fig. 3b). Hence, the data
Fig. 3 Cellular proliferation was evaluated by cell cycle by flow
cytometry analysis and detecting the expression of Ki-67
immunohistochemistry analysis. a Cell cycle modulation was restrained
comparedwith the negative control group. b The expression of Ki-67 was
reduced in cells transfected with miR-199a-3p
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revealed that miR-199a-3p up-regulation inhibited cell prolif-
eration in glioma.
Mir-199a-3p had no effect on invasion and apoptosis
capability
To determine whether the suppression of cellular prolif-
eration was due to decreased invasion capability or in-
creased apoptosis by the over-expression of miR-199a-
3p, we carried out a cell invasion assay and apoptosis
assay in vitro. At the same time, we detected the ex-
pression of MMP2 and caspase-3, which were related to
invasion and apoptosis capability, by Western blot anal-
ysis. Results indicated that no significant difference was
found between glioma cells’ over-expression of miR-
199a-3p and those with negative control oligonucleotide
(P>0.05; Fig. 4).
Relationship between miR-199a-3p and mTOR
Dates from the miRBase database and many studies [15,
17–19] had proved that mTOR was targeted by miR-199a-
3p. AIQurashi et al.[20] reported that miR-199a-3p acted a
role in tumor suppression by targeting mTORC1 and
mTORC2. Moreover, the expression of mTOR in U87 and
U51 cell lines obviously decreased after transfection with
miR-199a-3p (P<0.01; Fig. 2d). In addition, to estimate the
effect of miR-199a-3p on AKT/mTOR, we also found mTOR
protein levels and the phosphorylation of mTOR, AKT,
p70S6K, and 4E-BP1 decreased in miR-199a-3p groups by
Western blot analysis and immunofluorescence staining
(P<0.01; Figs. 5, 6, and 7). We further assessed the biological
significance of miR-199a-3p in the regulation of mTOR ex-
pression in glioma cells. Cells treated with NVP-BEZ235 to
inhibit mTOR activity and further transfected with miR-199a-
Fig. 4 The invasion and apoptosis were assessed and compared with
miR-199a-3p mimic negative control. a, b Invasion ability was
conducted by transwell invasion system. The number of invasive cells
was counted (ampersand, P>0.05). c, d Apoptosis capability was
detected by flow cytometry analysis (ampersand, P>0.05). e The
expression of MMP2 and caspase-3 were conducted (ampersand,
P>0.05)
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3p did not have a significant difference in inhibiting cell pro-
liferation (P>0.05; Fig. 6a).
Discussion
Varieties of previous powerful evidence revealed that
many miRNAs were abnormally expressed in human
glioma samples or cell lines [21–23]. Our pre-
experiment has shown that hsa-miR-199a-3p is one of
them. Furthermore, the dysregulation of miR-199a-3p in
glioma cell lines has similar effects to a tumor suppres-
sor gene or proto-oncogene. In our study, miR-199a-3p
suppresses glioma cellular growth and proliferation via
regulating AKT/mTOR signaling pathway.
MiRNAs bind to partially or fully complementary
sequences of mRNA in the 3′-untranslated region (3′-
UTR) to induce mRNA degradation or repress mRNA
translation [24, 25], then influencing the output of many
protein-coding genes [26]. For example, the down-
regulation or up-regulation of miR-199a-3p has been
shown to be related to cell proliferation, invasion, drug
resistance, apoptosis, and other processes in some kinds
of malignancy by targeting related genes. Although a
variety of miRNAs in glioma has been investigated
in vivo and in vitro, the research regarding miR-199a-
3p in glioma is limited. Gu and colleagues [27] reported
that three out of five glioma samples were significantly
elevated regarding miR-199a-3p when compared to two
normal brain tissues. However, in the present study, we
expended the number of glioma samples and examined
the expression of miR-199a-3p by real-time PCR.
Results showed miR-199-3p has a lower expression in
glioma samples and that there is no significant differen-
tial expression between low-grade and high-grade glio-
ma. Tumor specificity or instability may contribute to
the inconformity that comes from Gu and our team.
The mTOR is a ubiquitously expressed serine/
threonine (Ser/Thr) kinase that is a crucial regulator of
cell proliferation, metabolism, and other biological pro-
gresses in a lot of tumors [4, 28]. Inhibitors of mTOR,
for example, NVP-BEZ235 and miRNAs, block the
AKT/mTOR signaling pathway and suppress tumor
cells’ growth in many malignant tumors [29–31], in-
cluding glioma. Results from our study implied that
miR-199a-3p plays a critical role as a kind of inhibitor
of mTOR in glioma. The over-expression of miR-199a-
3p had a link to a lower level of protein expression of
mTOR and p-mTOR by bonding the mTOR gene and
then regulating the phosphorylation status of 4E-BP1,
p70S6K, and AKT in the mediation of cell growth and
cell proliferation. However, the changed level of p-AKT
after the inhibition of mTOR is controversial [32–34].
The argument will last; the reason is unsure but may be
due to varying experimental settings between different
investigators.
The invasion capability and apoptosis resistance of
tumor cells have been a barrier to therapeutic strategies.
Fornari et al. found that miR-199a-3p in human
hepatocarcinoma cells caused an obvious decrease of
Fig. 5 The expression of mTOR,
p-mTOR, AKT, p-AKT, p70S6K,
p-p70S6K, 4E-BP1, p-4E-BP1,
RhoA, and GAPDH in different
groups were detected by Western
blot analysis
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invasive potential [18]. In addition, Vignot et al. con-
firmed that inhibiting mTOR had a relation to promot-
ing apoptosis in some tumors [30, 35]. However, view-
ing the results from the present study, we tentatively
propose that the up-regulation of miR-199a-3p in glio-
ma cell lines, U87 and U251, has no significant differ-
ence in invasion and apoptosis. It seems that the effect
of the cell biological function through inhibiting the
expression of mTOR may vary with origins of tumors
or depends on cellular characteristics of tumor cells.
Besides that, miRNAs may not be an independent factor
at times or target potential genes other than mTOR.
Shafer et al. discovered rapamycin, one kind of inhibitor
of mTOR, combined with paclitaxel-induced apoptosis,
but not rapamycin alone [36].
Studies have reached an agreement with the view that
tumor cell proliferation is decreased if a lower level of
mTOR is obtained [37–39]. Gaining further insight into
the mechanisms of miR-199a-3p cell cycle modulation,
we find that miR-199a-3p targets mTOR and phosphor-
ylates p70S6K and 4E-BP1, downstream effector mole-
cules of mTOR, to regulate cell growth and prolifera-
tion. In addition, a decreased expression of the Ras
homolog gene family, member A (RhoA), which com-
bined with mTOR in the context of cytoskeletal regula-
tion [40, 41], is discovered in the high miR-199a-3p
group. Fornari et al.[15, 18] believed that cell cycle
modulation by mTOR inhibitors eventually led to an
increased G1 phase and decreased S phase. Indeed, re-
sults from our study indicated why glioma cell
Fig. 6 a Cellular proliferation
was assessed after 72 h of
incubation. Cells were treated
with NVP-BEZ235 of 100 nmol/
L for 24 h and then transfected
further with miR-199a-3p
(ampersand, P>0.05), when
compared with cells treated with
NVP-BEZ235 only. b, c
Immunofluorescence analysis
showed that the expression of
mTOR (asterisk, P<0.05) and
p-AKT (asterisks, P<0.01) was
apparently inhibited in cells by
the up-regulation of miR-199a-3p
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proliferation was limited when we elevated the expres-
sion of miR-199a-3p. In our study, we found mTOR
and p-mTOR, relative protein of AKT/mTOR signaling
pathway, were reduced in miR-199a-3p group. We be-
lieved miR-199a-3p suppresses the AKT/mTOR signal-
ing pathway and cell proliferation in vitro. Evidence
suggested that mTOR might be one of the targeted
genes of miR-199a-3p.
Taken together, miR-199a-3p has been found dysreg-
ulated in some malignancies. Further study proved it
was down-regulated in glioma samples and worked with
effects similar to the tumor suppressor gene. The effec-
tive role miR-199a-3p played in glioma can be attribut-
ed to the suppression of the AKT/mTOR signaling path-
way. Several decades had elapsed before therapeutic
strategies were found in connection with the cure of
glioma. Today, miR-199a-3p might provide another ap-
proach against glioma via targeting oncogenes.
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